Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Corporacion Parc Tauli116 enrolled

Overview

To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin

To observe the efficacy, effect on glycemic control, impact on BMI and incidence of adverse effects of Dulaglutide and to compare it to Liraglutide in individuals aged thirteen to eighteen who have Type 2 diabetes mellitus and are obese.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

116

Conditions

Type 2 Diabetes Treated With Insulin Obesity Adolescent Obesity

Interventions

DulaglutideDRUG

Dulaglutide injections

LiraglutideDRUG

Liraglutide injections

Eligibility

Sex: ALLMin age: 12 YearsMax age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 Diabetes Mellitus * Obese * Taking metformin * Male or female Exclusion Criteria: * Non obese * Not taking metformin * Taking other injectable diabetic medications

Locations (1)

Zainab Khan

Lahore, Punjab Province, Pakistan

Outcomes

Primary Outcomes

Glycemic level

HbA1c

Time frame: 24 weeks for the duration of the study

BMI

BMI measurements using weight and height measurements (anthropometric)

Time frame: 24 weeks for the duration of the study

Adverse effects

Recording of adverse effects

Time frame: 24 weeks for the duration of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.